Research Published in JSES Indicates that the Catalyst™ CSR Total Shoulder System Outperforms Traditional Stemmed Implants

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has announced the publication of a new study in the Journal of Shoulder and Elbow Surgery that shows positive clinical outcomes using the Catalyst™ CSR total shoulder system, compared to standard stemmed TSAs.

The study, Stemless Total Shoulder Arthroplasty Using a Novel Multiplanar Osteotomy and Elliptical Humeral Head Results in Both Improved Early Range of Motion and Radiographic Center of Rotation Compared to Standard Total Shoulder Arthroplasty (Budge, Orvets), tested and compared early postoperative range of motion (ROM) and restoration of radiographic center of rotation (COR), using the Catalyst anatomic shoulder system and standard stemmed TSAs.

The results demonstrate that patients who received the Catalyst anatomic shoulder replacement achieved better ROM at 6 and 12 weeks, and improved restoration of the radiographic COR when compared to patients who received a standard stemmed TSA with a spherical humeral head.

“The Catalyst CSR anatomic shoulder system uses a multiplanar osteotomy that allows for superior precision and accuracy in shoulder replacement, while preserving more of the patient’s native bone,” said Matthew Budge, M.D., orthopedic surgeon, Kaiser Permanente. “This novel approach leverages both reproduction of the patient’s native humeral head height and offset with an ellipsoid anatomic head. Together, these attributes contributed to a faster recovery time compared to standard stemmed TSA.”

This study was a retrospective review of 50 consecutive primary patients by a single surgeon. Data was collected at 6 weeks, 12 weeks, 6 months, and 12 months postoperative on patients who received 25 stemmed implants from Depuy, Stryker (Wright Medical), Lima & Zimmer Biomet and 25 Catalyst anatomic implants.

95% of patients in the Catalyst group had a change in COR <3mm, compared to only 60% in the stemmed group, indicating that the multiplanar osteotomy and ellipsoid anatomic head result in more consistent reproduction of the humeral head anatomy, supporting better ROM.

“Faster recoveries can be attributed to a combination of several factors working in unison,” said Carl O’Connell, CEO and president of Catalyst. “A more anatomically shaped, ellipsoid humeral head design better mimics the patient’s natural anatomy. Our precision multiplanar osteotomy instrumentation removes a minimal amount of bone and consistently allows for better restoration of the native humeral joint line. And patented, oblique glenoid instruments allow for the glenoid to be prepared with less muscle retraction than a traditional perpendicular approach.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.